OTCPK:LXXG.F

Stock Analysis Report

Executive Summary

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of automated pathogen detection platform in clinical and life sciences industries.

Snowflake

Fundamentals

Mediocre balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has LexaGene Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.8%

LXXG.F

2.0%

US Medical Equipment

1.8%

US Market


1 Year Return

-30.4%

LXXG.F

13.3%

US Medical Equipment

7.3%

US Market

Return vs Industry: LXXG.F underperformed the US Medical Equipment industry which returned 13.3% over the past year.

Return vs Market: LXXG.F underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

LXXG.FIndustryMarket
7 Day-2.8%2.0%1.8%
30 Day-21.2%-1.8%-0.7%
90 Day-31.2%-0.5%0.06%
1 Year-30.4%-30.4%14.2%13.3%9.7%7.3%
3 Yearn/a70.5%65.3%46.3%36.9%
5 Yearn/a127.0%101.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is LexaGene Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is LexaGene Holdings undervalued compared to its fair value and its price relative to the market?

15.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate LXXG.F's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate LXXG.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LXXG.F is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: LXXG.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate LXXG.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LXXG.F is overvalued based on its PB Ratio (15.3x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is LexaGene Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LexaGene Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of LXXG.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access LexaGene Holdings's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has LexaGene Holdings performed over the past 5 years?

-52.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: LXXG.F is unprofitable, and losses have increased over the past 5 years at a rate of -52.6% per year.

Accelerating Growth: Unable to compare LXXG.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LXXG.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: LXXG.F has a negative Return on Equity (-465.76%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: LXXG.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: LXXG.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is LexaGene Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: LXXG.F's short term assets ($1.6M) exceeds its short term liabilities ($456.2K)

Long Term Liabilities: LXXG.F's short term assets (1.6M) do not cover its long term liabilities (1.7M)


Debt to Equity History and Analysis

Debt Level: LXXG.F is debt free.

Reducing Debt: LXXG.F had no debt 5 years ago.


Balance Sheet

Inventory Level: LXXG.F has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if LXXG.F's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LXXG.F has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: LXXG.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of -73.9% each year


Next Steps

Dividend

What is LexaGene Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate LXXG.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LXXG.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if LXXG.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LXXG.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LXXG.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of LexaGene Holdings's salary, the management and board of directors tenure and is there insider trading?

2.5yrs

Average management tenure


CEO

Jack Regan 0

3yrs

Tenure

US$299,650

Compensation

Dr. John F. Regan, also known as Jack, is the Founder of LexaGene Holdings Inc. and has been its Chairman of the Board since September 12, 2017 and Chief Executive Officer & Director since October 12, 2016 ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Jack's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Jack's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.5yrs

Average Tenure

Experienced Management: LXXG.F's management team is considered experienced (2.5 years average tenure).


Board Age and Tenure

1.7yrs

Average Tenure

Experienced Board: LXXG.F's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$6,52002 Apr 19
Manohar Furtado
EntityIndividual
Role
Member of the Board of Directors
Director
Shares10,030
Max PriceUS$0.65
BuyUS$5,01302 Apr 19
John Regan
EntityIndividual
Role
Chief Executive Officer
Founder
Shares10,308
Max PriceUS$0.49
BuyUS$4,86301 Apr 19
Darrel Rebeck
EntityIndividual
Role
Member of the Board of Directors
President & Director
Shares10,000
Max PriceUS$0.49

Ownership Breakdown


Management Team

  • Al Fabbro (62yo)

    Vice President of Corporate Development

    • Tenure: 2.9yrs
  • Daryl Rebeck

    President & Director

    • Tenure: 4.5yrs
    • Compensation: US$257.10k
  • Jack Regan

    Founder

    • Tenure: 3yrs
    • Compensation: US$299.65k
  • Jeff Mitchell

    CFO, Treasurer & Corporate Secretary

    • Tenure: 1.6yrs
    • Compensation: US$176.82k

Board Members

  • Joseph Caruso (60yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$10.80k
  • Kimothy Smith

    Member of Scientific Advisory Board

    • Tenure: 0.8yrs
  • Daryl Rebeck

    President & Director

    • Tenure: 4.5yrs
    • Compensation: US$257.10k
  • James Marsden

    Member of Scientific Advisory Board

    • Tenure: 0.5yrs
  • Jack Regan

    Founder

    • Tenure: 3yrs
    • Compensation: US$299.65k
  • Tom Slezak

    Director

    • Tenure: 3yrs
  • Manohar Furtado

    Director

    • Tenure: 2.2yrs
  • Shawn Stevens

    Member of Scientific Advisory Board

    • Tenure: 0.8yrs

Company Information

LexaGene Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: LexaGene Holdings Inc.
  • Ticker: LXXG.F
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$36.291m
  • Listing Market Cap: CA$27.631m
  • Shares outstanding: 72.58m
  • Website: https://www.lexagene.com

Number of Employees


Location

  • LexaGene Holdings Inc.
  • 500 Cummings Center
  • Suite 4550
  • Beverly
  • Massachusetts
  • 1915
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LXGTSXV (TSX Venture Exchange)YesNew Common SharesCACADOct 2016
5XS2DB (Deutsche Boerse AG)YesNew Common SharesDEEUROct 2016
LXXG.FOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDOct 2016

Biography

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of automated pathogen detection platform in clinical and life sciences industries. The company’s ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 00:37
End of Day Share Price2019/10/18 00:00
Earnings2019/05/31
Annual Earnings2019/02/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.